---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-252618"
form_type: "8-K"
ticker: "XOMA"
cik: "0000791908"
company_name: "XOMA Royalty Corp"
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T04:07:16.531563+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# XOMA Q3: Revenue $7.2M, net loss $17.2M ($14M impairment); Twist 50% interest acquired

## Summary
- Total income/revenue of $7.2M in Q3 2024 vs $0.8M in Q3 2023; cash receipts $9.9M.
- Net loss of $17.2M vs $5.5M loss, driven by $14M non-cash impairment on Agenus royalty purchase agreement.
- Acquired 50% economic interest in Twist Bioscience's 60+ partnered early-stage programs for $15M.
- Cash and cash equivalents of $146.8M at Sept 30, 2024, down from $159.6M at Dec 31, 2023.
- Zevra's MIPLYFFA (arimoclomol) received FDA approval for Niemann-Pick disease type C, adding commercial royalty.

## SEC filing metadata
- accession: 0001193125-24-252618
- form_type: 8-K
- ticker: XOMA
- cik: 0000791908
- company_name: XOMA Royalty Corp
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/791908/000119312524252618/0001193125-24-252618-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/791908/000119312524252618/d835519d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-252618
- JSON: https://secwatch.observer/filing/0001193125-24-252618.json
- Plain text: https://secwatch.observer/filing/0001193125-24-252618.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.